Uptravi Can Help PAH Patients at Greatest Risk of Death, Registry Data Show

Uptravi Can Help PAH Patients at Greatest Risk of Death, Registry Data Show

291609

Uptravi Can Help PAH Patients at Greatest Risk of Death, Registry Data Show

More than three-quarters (76%) of adults with pulmonary arterial hypertension (PAH) being treated with Uptravi (selexipag) either saw no increase or a decline in their risk of death over one year, a study based real-world data reports. These findings — in nearly 500 people taking part in an ongoing registry, with most determined at entry to have an intermediate or high one-year mortality risk — underscore the importance of risk assessments in determining treatment goals…

You must be logged in to read/download the full post.